View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Zealand Pharma convenes its Annual General Meeting 2026

Zealand Pharma convenes its Annual General Meeting 2026 Company announcement – No. 2 / 2026 Zealand Pharma convenes its Annual General Meeting 2026 Copenhagen, Denmark, February 19, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, hereby convenes its Annual General Meeting 2026. The Board of Directors of Zealand Pharma A/S hereby convenes the Annual General Meeting of the Company to be held on: Thursday, 26 March 2026 at 03:00 PM (CET) / 9:00 (ET) The Annual General Meet...

Carole Braudeau
  • Carole Braudeau

Credit Morning 02/19/2026

Constellium: very strong Q4 2025 results with the momentum continuing into H1 2026|Eramet publishes weak results for 2025 but takes radical measures to rapidly improve its financial structure, notably with a plan to strengthen its equity capital by € 500m|AF-KLM: Unit costs under control enabling good profitability levels|

Carole Braudeau
  • Carole Braudeau

Morning Crédit 19/02/2026

Constellium: very strong Q4 2025 results with the momentum continuing into H1 2026|Eramet publie de faibles résultats 2025 mais prend des mesures radicales pour améliorer rapidement la structure financière, notamment avec un projet de renforcement des fonds propres de 500 m EUR|AF-KLM: Unit costs under control enabling good profitability levels|

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

AEGON: Uneventful results, US weaker, underlying OCG in line / Air France-KLM: Productivity gains starting to filter through / Arcadis: Weak revenues and EBITA, but strong NWC / Ascencio: Results in line, no concerns on Carrefour Belgium exposure / Azelis: Persisting softness in 4Q25, continued focus on costs and cash / BAM Group: Solid 2H25 results, 2026 outlook in line / Belgian telecoms: Telenet improved net adds, to relist as part of Ziggo in 2027, Liberty to sell half of its 66% Wyre stake ...

Wim Lewi
  • Wim Lewi

VGP FY25 results come a bit short, a new JV partner compensates

VGP reported FY25 net profit of EUR €290.4m vs. €373.6m expected, mainly due to non-EPRA financial costs in the JV. The recurrent earnings also came up short with €139m vs. our estimated €180m, mainly on €30m lower realized gains and €22m higher interest costs. Unrealized gains were strong at €183.0m vs. €185.2m expected. This indicates that the FV uplift is related to sound development activity. The NTA per share rose 9.1%. New leases signed amounted to €56.9m. FY25 completions at 494k sqm vs. ...

Mathijs Geerts Danau
  • Mathijs Geerts Danau

Zealand Pharma FY25 results: Looking forward to petrelintide phase 2 d...

Zealand reported FY25 results, ending the year with cash of DKK 15,109m (YE24: DKK 9,022m), reinforcing the strong balance sheet. OPEX increased to DKK 2,101m (FY24: 1,324m) driven by increased R&D spending related to the ongoing petrelintide phase 2 trials. For FY26, Zealand guides OPEX of DKK 2,700-3,300m, due to continued investment in the petrelintide franchise. We look forward to the read-out of the petrelintide phase 2 trial in obesity expected in 1Q26, which could confirm petrelintide's p...

Guy Sips ... (+9)
  • Guy Sips
  • Hilde Van Boxstael
  • Kristof Samoy
  • Mathijs Geerts Danau
  • Michiel Declercq
  • Thibault Leneeuw
  • Thomas Couvreur
  • Wim Hoste
  • Wim Lewi

Morning Notes : ABI BB, AGN NA, ARCAD NA, BESI NA, ENX FP, GIMB BB, HY...

: ABI BB, AGN NA, ARCAD NA, BESI NA, ENX FP, GIMB BB, HYL BB, IBAB BB, KIN BB, MTLS US, VGP BB, AZE BB, ZEAL DC

Martin Marandon-Carlhian ... (+2)
  • Martin Marandon-Carlhian
  • Stephane Houri
Roy Külter ... (+2)
  • Roy Külter
  • Steven Boumans
Martin Marandon-Carlhian ... (+2)
  • Martin Marandon-Carlhian
  • Stephane Houri
Guy Sips
  • Guy Sips

Kinepolis Group Lower results, as expected, impacted by less visitors ...

Against the backdrop of ongoing restructuring and recapitalization in Hollywood, Kinepolis received in FY25 -5.8% y/y visitors or 30.7m, down. Kinepolis Group indicated that -although 2025 saw some notable successes- mainly in the animation and horror genres, the year was affected by a less favourable comparison base, partly due to the exceptional success of 'Inside Out 2' and several French films in 2024. We maintain our positive stance (Buy, € 42 Target Price) as Kinepolis highlighted that F...

Stefano Toffano
  • Stefano Toffano
 PRESS RELEASE

Kinepolis delivered solid results in 2025

Kinepolis delivered solid results in 2025 Kinepolis delivered solid results in 2025 Regulated information 19 February 2026, 7:00 a.m. CET  Kinepolis delivered solid results in 2025 in a still challenging environment. Despite an incomplete Hollywood slate, the absence of the major French box‑office successes of 2024 and negative currency effects, Kinepolis succeeded in limiting the revenue decline to -2.3% (with -5.8% visitors) compared with the previous year. With this, Kinepolis achieved a robust adjusted EBITDAL of € 128.2 million (-3.4%) and an adjusted net result that remained virtua...

 PRESS RELEASE

Kinepolis a réalisé des résultats solides en 2025

Kinepolis a réalisé des résultats solides en 2025 Kinepolis a réalisé des résultats solides en 2025 Information réglementée 19 février 2026, 7:00 CET Kinepolis a réalisé en 2025 des résultats solides dans un contexte toujours exigeant. Malgré une offre hollywoodienne incomplète, l’absence des grands succès français de 2024 et des effets de change négatifs, Kinepolis a réussi à limiter la baisse du chiffre d’affaires à -2,3% (avec -5,8% de visiteurs) par rapport à l’année précédente. Kinepolis enregistre ainsi un EBITDAL ajusté robuste de € 128,2 millions (-3,4%) et un résultat net ajusté...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch